News & Updates

Show Multimedia Only
HCC risk in CHB patients persists 12 years after HBsAg loss
HCC risk in CHB patients persists 12 years after HBsAg loss
21 Mar 2023 byChristina Lau

Patients with chronic hepatitis B (CHB) still have a non-negligible risk of hepatocellular carcinoma (HCC) 12 years after achieving hepatitis B surface antigen (HBsAg) seroclearance, especially if cirrhosis is present, a large territory-wide real-world study in Hong Kong has shown.

HCC risk in CHB patients persists 12 years after HBsAg loss
21 Mar 2023
PCSK9 inhibition tied to decreased psoriasis risk
PCSK9 inhibition tied to decreased psoriasis risk
20 Mar 2023
Telbivudine use during pregnancy safe, effective in HBsAG-positive mothers
Telbivudine use during pregnancy safe, effective in HBsAG-positive mothers
20 Mar 2023
Frequent aspirin use protects against ovarian cancer even in women with genetic predisposition
Frequent aspirin use protects against ovarian cancer even in women with genetic predisposition
19 Mar 2023

Genetic susceptibility to ovarian cancer does not appear to modify the protective association between frequent aspirin use and the risk of developing the cancer, as shown in a study.

Frequent aspirin use protects against ovarian cancer even in women with genetic predisposition
19 Mar 2023